Show simple item record

dc.contributor.authorLin, S
dc.contributor.authorLian, D
dc.contributor.authorLiu, W
dc.contributor.authorHaig, A
dc.contributor.authorLobb, I
dc.contributor.authorHijazi, A
dc.contributor.authorRazvi, H
dc.contributor.authorBurton, J
dc.contributor.authorWhiteman, M
dc.contributor.authorSener, A
dc.date.accessioned2018-05-22T09:56:04Z
dc.date.issued2018-03-06
dc.description.abstractOBJECTIVES: To assess the effects of slow-releasing H2S donor GYY4137 on post-obstructive renal function and injury following unilateral ureteral obstruction (UUO) by using the UUO and reimplantation (UUO-R) model in rats and to elucidate potential mechanisms by using an in vitro model of epithelial-mesenchymal transition (EMT). METHODS: Male Lewis rats underwent UUO at the left ureterovesical junction. From post-operative day (POD) 1-13, rats received daily intraperitoneal (IP) injection of phosphate buffered saline (PBS, 1 mL) or GYY4137 (200 μmol/kg/day in 1 mL PBS, IP). On POD 14, the ureter was reimplanted back into the bladder, followed by a right nephrectomy. Urine and serum samples were collected to monitor renal function. On POD 30, the left kidney was removed and tissue sections were stained with H&E, TUNEL, CD68, CD206, myeloperoxidase, and Masson's trichrome to determine cortical thickness, apoptosis, inflammation, and fibrosis. In our in vitro model of EMT, NRK52E cells were treated with 10 ng/mL TGF-β1, 10 μM GYY4137 and/or 50 μM GYY4137. Western blot analysis was performed to determine the expression of E-cadherin, vimentin, Smad7 and TGF-β1 receptor II (TβRII). RESULTS: GYY4137 led to a moderate decrease in post-obstructive serum creatinine, cystatin C and FENa. We also observed a trend towards a decrease in post-obstructive proteinuria following GYY4137 treatment. Histologically, we observed a significant decrease in apoptosis, inflammation, and fibrosis. Furthermore, our in vitro studies demonstrate that in the presence of TGF-β1, GYY4137 significantly decreases vimentin and TβRII and significantly increases E-cadherin and Smad7. CONCLUSIONS: H2S may help to accelerate the recovery of renal function post-obstruction and attenuates renal injury associated with UUO. It is possible that H2S mitigates fibrosis by regulating the TGF-β1-mediated EMT pathway. Taken together, our data suggest that H2S may be a potential novel therapy for improving renal function and limiting renal injury associated with obstructive uropathy.en_GB
dc.description.sponsorshipThis work was supported by the Canadian Institute of Health Research.en_GB
dc.identifier.citationVol. 76, pp. 16-28.en_GB
dc.identifier.doi10.1016/j.niox.2018.03.002
dc.identifier.urihttp://hdl.handle.net/10871/32958
dc.language.isoenen_GB
dc.publisherElsevieren_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/29522906en_GB
dc.rights.embargoreasonUnder embargo until 06 March 2019 in compliance with publisher policy.en_GB
dc.rights© 2018 Elsevier Inc. All rights reserved.en_GB
dc.subjectEpithelial mesenchymal transitionen_GB
dc.subjectHydrogen sulfideen_GB
dc.subjectRenal functionen_GB
dc.subjectRenal injuryen_GB
dc.subjectTransforming growth factor beta 1en_GB
dc.subjectUnilateral ureteral obstructionen_GB
dc.titleDaily therapy with a slow-releasing H2S donor GYY4137 enables early functional recovery and ameliorates renal injury associated with urinary obstruction.en_GB
dc.typeArticleen_GB
dc.identifier.issn1089-8603
exeter.place-of-publicationUnited Statesen_GB
dc.descriptionThis is the author accepted manuscript. The final version is available from Elsevier via the DOI in this record.en_GB
dc.identifier.journalNitric Oxideen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record